Roche (RHHBY.US) announces the latest data from the Phase III study of Pertuzumab in breast cancer.

According to the Wisdom Financial APP, on May 13, Roche (RHHBY.US) announced the final overall survival (OS) results of the phase III APHINITY study, which is aimed at HER2-positive early breast cancer patients. The study results after ten years showed statistical significance: compared to patients receiving Herceptin, chemotherapy, and placebo treatment, patients receiving Perjeta, Herceptin (trastuzumab emtansine), and chemotherapy as adjuvant treatment after surgery had a 17% reduced risk of death.